Report cover image

Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Publisher GlobalData
Published Jun 27, 2022
Length 68 Pages
SKU # GBDT17345917

Description

Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Polymyositis and Dermatomyositis therapeutics.

In 2022, there will be more than 349,000 diagnosed prevalent cases of polymyositis (PM) and 165,000 diagnosed prevalence case of dermatomyositis (DM) across 16 pharmaceutical markets.

There are 13 FDA approved drugs available for the treatment of PM/DM.

The PM and DM pipeline consists of over 21 pharmaceuticals spanning all stages of development, with approximately 50% of drugs in mid to late-stage development.

Commercial sponsors dominate clinical trial development in PM and DM, with the US emerging as the key countries for conducting trials in PM and DM.

Deals involving acquisition of PM/DM assets are the most common types of deals in the US and Europe.

A total of five players are currently developing newer products for the treatment of PM/DM in the late-stage pipeline, suggesting a drastic change in the PM/DM market landscape in the immediate future.

Scope

GlobalData’s Polymyositis and Dermatomyositis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Polymyositis and Dermatomyositis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Polymyositis and Dermatomyositis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

68 Pages
  • Key Findings
  • Disease Overview
    • Epidemiology Overview: Diagnosed Prevalent Cases of PM in 2022 and 2027
    • Epidemiology Overview: Diagnosed Prevalent Cases of DM in 2022 and 2027
    • Treatment Guidelines
    • Marketed Drugs Overview
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Route of Administration
    • Pipeline Drugs Overview - Phase II and Phase III Pipeline Drugs in PM and DM
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - PTSR and LoA in Musculoskeletal Disorders and PM
    • Pipeline Drugs - PTSR and LoA in Musculoskeletal Disorders and DM
    • Pipeline Drugs - Drug-Specific PTSRs and LoAs in PM and DM
    • Clinical Trials in PM and DM - Historical Overview
    • Clinical Trials in PM and DM - Overview by Phase
    • Clinical Trials in PM and DM - Overview by Status
    • Clinical Trials in PM and DM - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in PM and DM - Trials with a Virtual Component
    • Clinical Trials in PM and DM - Geographic Overview
    • Clinical Trials in PM and DM - Single-Country and Multinational Trials by Region
    • Clinical Trials in PM and DM - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in PM and DM - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in PM and DM - Overview by Endpoint Status
    • Clinical Trials in Polymyositis and Dermatomyositis - Overview by Race and Ethnicity
    • Clinical Trials in PM and DM - Enrollment Data
    • Clinical Trials in PM and DM - Overview of Sites by Geography
    • Clinical Trials in PM and DM - Top 10 Countries for Trial Sites
    • Clinical Trials in PM and DM - Top 10 Sites Globally
    • Clinical Trials - Feasibility Analysis for PM: Geography Overview
    • Clinical Trials - Feasibility Analysis for DM: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for PM
    • Clinical Trials - Feasibility Analysis: Benchmark Models for DM
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in PM and DM by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in PM and DM
    • Commercial Assessment - Key Market Players in PM and DM
    • Future Market Catalysts - Upcoming Market Catalysts in PM and DM
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis
    • About the Authors
  • Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us